Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors
about
Effects of beta3-adrenergic receptor activation on rat urinary bladder hyperactivity induced by ovariectomyRegulation of urinary bladder function by protein kinase C in physiology and pathophysiologyCajal-like interstitial cells as a novel target in detrusor overactivity treatment: true or myth?The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder diseaseOn benzofuroindole analogues as smooth muscle relaxantsLarge-conductance voltage- and Ca2+-activated K+ channel regulation by protein kinase C in guinea pig urinary bladder smooth muscle.Nerve-released acetylcholine contracts urinary bladder smooth muscle by inducing action potentials independently of IP3-mediated calcium release.The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum.Calcium Antagonists Use and Its Association with Lower Urinary Tract Symptoms: A Cross-Sectional Study.Prospective pharmacologic therapies for the overactive bladderRole of KIT-Positive Interstitial Cells of Cajal in the Urinary Bladder and Possible Therapeutic Target for Overactive BladderControl of urinary drainage and voiding.Bladder smooth muscle strip contractility as a method to evaluate lower urinary tract pharmacology.Urinary Bladder Dysfunction in Transgenic Sickle Cell Disease Miceβ3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinaseRole of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.Novel role for the transient potential receptor melastatin 4 channel in guinea pig detrusor smooth muscle physiologyExtracellular UDP enhances P2X-mediated bladder smooth muscle contractility via P2Y(6) activation of the phospholipase C/inositol trisphosphate pathway.Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.BRL37344, a β3-adrenergic receptor agonist, decreases nerve-evoked contractions in human detrusor smooth muscle isolated strips: role of BK channels.In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms.Similarities and differences in the autonomic control of airway and urinary bladder smooth muscleBasic mechanisms of urgency: roles and benefits of pharmacotherapyOn the Site and Mechanism of Action of β3-Adrenoceptor Agonists in the BladderWhat do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).Mirabegron in the treatment of overactive bladder.Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "overactive bladder".Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms.Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms.Therapeutic targets for overactive bladder other than smooth muscle.Muscarinic receptor subtypes and signalling involved in the attenuation of isoprenaline-induced rat urinary bladder relaxationIs overactive bladder a nervous or bladder disorder? Autonomic imaging in patients with overactive bladder via dynamic pupillometry.Evaluation of the incidence and risk factors associated with persistent frequency in interstitial cystitis/bladder pain syndrome and the efficacy of antimuscarinic treatment.Phorbol 12,13-dibutyrate-induced, protein kinase C-mediated contraction of rabbit bladder smooth muscle.Mirabegron.Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder.Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder.Histological determination of the areas enriched in cholinergic terminals and M2 and M3 muscarinic receptors in the mouse central auditory system.
P2860
Q24648758-CB486E7A-EB1A-47AA-A859-5EC2019C57ACQ26780063-37C3AC9D-0060-406B-94D8-718B11EA9BD7Q26861452-F7D09C2D-F8DB-414F-9EDA-A8F37D030FC9Q26864937-BB4E99CE-D387-4951-8268-7772FED1BC24Q27001453-C595FC07-E654-412D-94A9-267784448D20Q33901908-7C8D835A-3162-4BCB-823B-3CC704C0AB1AQ34150201-F4DFFAE3-8119-4C2A-A68C-AE3B25029DADQ34709612-A89E4E5D-A50B-4EED-82D3-72A97AF2F504Q34785537-8C47CD09-7323-4F91-BCC2-722263D6FE69Q35076367-84CA06E3-F57F-4756-A683-5025E09D25AEQ35116336-60BB6816-E54F-4A85-94EB-CF75ADB81363Q35144401-43BE94AA-0F8E-4ABE-B6B0-7E0BC143A930Q35618693-FF7F2CD9-AB38-4796-8BAD-7F3E1B01A1FDQ35737367-BF4F67B5-30C6-4127-BAD4-6DF81FCF407AQ35762174-6937F040-6B9A-4C8B-9915-9857E5D90637Q36381156-3101D11F-7092-4E07-BF4B-A3A5E9968B2AQ36699604-4BAB77B3-34A9-46CD-8D5A-6430268A5563Q36788773-63BF7E1C-7DF0-4C31-BED2-B1A37EE647CBQ37119868-44242A79-2F55-4097-99CB-4FE3BD7154E3Q37136287-89D63F66-5E24-4E8E-B1AF-61F9B92DA67CQ37159996-E1B57CAF-1F97-477E-96D9-8B5C8B05BE47Q37189382-A2B02CC5-775A-411A-9D9F-982D7AF057E5Q37428717-8877280B-4D1A-4849-BD15-3E7CEA46EBA9Q37737698-C60DE370-92E0-4DB4-8B9D-CE3AC8C3CF5CQ38127144-EB93A7F8-2A0C-4EDF-848F-0746DDF3E34DQ38152756-F49C0912-C3D5-487F-A11F-387AA4745D35Q38193896-B70850A8-4C92-438B-B248-D3738BC05C32Q38197276-377B211C-24EA-4AC3-8D7A-0B02EC2FFB99Q38231747-EB47A529-8921-49DB-8786-4CEFC1E71F8EQ38262087-8EA9130F-0AC9-4BD9-8607-15B620F18163Q38336214-99EF826C-8142-48D0-AF28-C2511CF6A473Q38364035-F8F55A5D-5F23-480E-9926-1F33C1E027F1Q39253820-97ACFE35-238C-484F-8BB3-FE5FEEF2F361Q39677795-798B8FBE-91F3-4D9D-B316-D328A0480C62Q40059471-0D4214DC-BBAF-483F-ADFB-726A93EB8AB8Q40092633-B7D6D8C1-15CB-4DC6-89DC-BD556EEF46B1Q41266128-76304DF4-250D-470D-9ACC-0BD77146E142Q42261505-50BE6DB3-4588-4C92-BB5F-0289745D61EEQ42655948-09FF3493-A71B-490A-A35B-B0D8944861B7Q42954114-4F0E2CE0-8C2E-4939-A584-7D8417B3AC5D
P2860
Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Signal transduction underlying ...... ceptors and beta-adrenoceptors
@en
type
label
Signal transduction underlying ...... ceptors and beta-adrenoceptors
@en
prefLabel
Signal transduction underlying ...... ceptors and beta-adrenoceptors
@en
P2093
P2860
P921
P1476
Signal transduction underlying ...... ceptors and beta-adrenoceptors
@en
P2093
Alan S Braverman
Elfaridah P Frazier
Michael R Ruggieri
Stephan L M Peters
P2860
P2888
P304
P356
10.1007/S00210-007-0208-0
P577
2007-12-04T00:00:00Z
2008-06-01T00:00:00Z